Antiretrovirals for preexposure prophylaxis (PrEP) among high-risk persons without HIV infection has emerged as an effective HIV prevention strategy. With the recent approval of oral tenofovir–emtricitabine for PrEP in high-risk populations, clinicians can now prescribe PrEP to their at-risk patients and thus should become familiar with it. This review outlines current knowledge about PrEP in primary care, including identifying persons likely to benefit from PrEP; counseling to maximize adherence and reduce potential increases in risky behavior; and monitoring for potential drug toxicities, HIV acquisition, and antiretroviral drug resistance.
Topics:
hiv, tenofovir, emtricitabine, anti-retroviral agents, tenofovir/emtricitabine, hiv prevention, iprex trial, caprisa trial, ...
Ann Intern Med. 2012;157(7):490-497. doi:10.7326/0003-4819-157-7-201210020-00510